Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

First biosimilar Humira launches in India

AbbVie to face competition for world’s biggest-selling drug

- PMLiVE

Private sector on rise in England’s NHS, says BMJ

One-third of NHS contracts have gone to private providers since healthcare reforms

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

- PMLiVE

FDA approves Ipsen drug to treat rare tumours

Green light for Somatuline Depot in cancer of the neuroendocrine system

- PMLiVE

Novartis’ acromegaly therapy cleared by FDA

Signifor LAR shows superior efficiency to older treatments

- PMLiVE

NICE recommends Pradaxa in blood clot indication

Boehringer drug backed to treat and prevent deep vein thrombosis and pulmonary embolism

- PMLiVE

The use of search engines in health

The vast majority of health seekers use search engines as a starting point to gain information on a disease or illness

FlowMetric Diagnostics names president

Amy Williams has over 25 years of experience in life sciences

- PMLiVE

EMA: Lack of evidence for Ebola treatments

Not enough data to draw conclusions on effectiveness of experimental drugs

- PMLiVE

Patent cliff losses set to cost pharma $65bn by 2019

Lilly, AZ and Otsuka to be hit hard, says GlobalData

- PMLiVE

NICE backs Pfizer drug in kidney cancer

Inlyta near end of two-year struggle for recommendation

- PMLiVE

Germany’s IQWiG delivers bad news for Bayer’s Eylea

Says drug provides no additional benefit over Novartis’ rival Lucentis in eye condition

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links